Scott D Nei1, Patrick M Wieruszewski2,3, Rachael Scott2, Kevin L Greason4. 1. Department of Pharmacy, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. nei.scott@mayo.edu. 2. Department of Pharmacy, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. 3. Multidisciplinary Epidemiology and Translational Research in Intensive Care (METRIC) Group, Mayo Clinic, Rochester, MN, USA. 4. Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, USA.
Abstract
INTRODUCTION: Dual antiplatelet therapy (DAPT) was the initial antithrombotic regimen of choice following transcatheter aortic valve replacement (TAVR). Subsequent identification of subclinical valve thrombosis in high-risk patients has questioned whether warfarin should be used as an alternative to DAPT for some patients. OBJECTIVE: The aim of this study was to compare thromboembolic events, bleeding, and all-cause mortality between DAPT and warfarin following TAVR. METHODS: This was a single-center, retrospective review of TAVR patients who received DAPT or warfarin following TAVR between 2008 and 2018. The primary endpoint was occurrence of thromboembolic events during the hospital stay and 1-year follow-up, while secondary endpoints included bleeding and all-cause mortality. RESULTS: Of the included 764 patients, 193 received DAPT and 571 received warfarin. The median Society of Thoracic Surgeons (STS) Predicted Risk of Mortality (PROM) scores were 8.3% for the DAPT group and 6.5% for the warfarin group. The primary endpoint occurred 30 times (3.9%) during the study timeframe. No differences in thromboembolic events between the DAPT and warfarin groups were found (4.14% vs. 3.85%; p = 0.857), and there was no difference in bleeding (6.22% vs. 5.08%; p = 0.544) or risk of mortality (hazard ratio 0.59, 95% confidence interval 0.33-1.06; p = 0.076). CONCLUSIONS: In this study, warfarin had similar effectiveness and safety, compared with DAPT, for antithrombotic management post-TAVR. For patients whom the provider deemed anticoagulation is indicated, our data suggest warfarin is a well-tolerated option following TAVR in intermediate- and high-risk STS score patients.
INTRODUCTION: Dual antiplatelet therapy (DAPT) was the initial antithrombotic regimen of choice following transcatheter aortic valve replacement (TAVR). Subsequent identification of subclinical valve thrombosis in high-risk patients has questioned whether warfarin should be used as an alternative to DAPT for some patients. OBJECTIVE: The aim of this study was to compare thromboembolic events, bleeding, and all-cause mortality between DAPT and warfarin following TAVR. METHODS: This was a single-center, retrospective review of TAVR patients who received DAPT or warfarin following TAVR between 2008 and 2018. The primary endpoint was occurrence of thromboembolic events during the hospital stay and 1-year follow-up, while secondary endpoints included bleeding and all-cause mortality. RESULTS: Of the included 764 patients, 193 received DAPT and 571 received warfarin. The median Society of Thoracic Surgeons (STS) Predicted Risk of Mortality (PROM) scores were 8.3% for the DAPT group and 6.5% for the warfarin group. The primary endpoint occurred 30 times (3.9%) during the study timeframe. No differences in thromboembolic events between the DAPT and warfarin groups were found (4.14% vs. 3.85%; p = 0.857), and there was no difference in bleeding (6.22% vs. 5.08%; p = 0.544) or risk of mortality (hazard ratio 0.59, 95% confidence interval 0.33-1.06; p = 0.076). CONCLUSIONS: In this study, warfarin had similar effectiveness and safety, compared with DAPT, for antithrombotic management post-TAVR. For patients whom the provider deemed anticoagulation is indicated, our data suggest warfarin is a well-tolerated option following TAVR in intermediate- and high-risk STS score patients.
Authors: Martin B Leon; Craig R Smith; Michael Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; David L Brown; Peter C Block; Robert A Guyton; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Pamela S Douglas; John L Petersen; Jodi J Akin; William N Anderson; Duolao Wang; Stuart Pocock Journal: N Engl J Med Date: 2010-09-22 Impact factor: 91.245
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Rick A Nishimura; Catherine M Otto; Robert O Bonow; Blase A Carabello; John P Erwin; Lee A Fleisher; Hani Jneid; Michael J Mack; Christopher J McLeod; Patrick T O'Gara; Vera H Rigolin; Thoralf M Sundt; Annemarie Thompson Journal: Circulation Date: 2017-03-15 Impact factor: 29.690
Authors: Michael J Mack; Martin B Leon; Vinod H Thourani; Raj Makkar; Susheel K Kodali; Mark Russo; Samir R Kapadia; S Chris Malaisrie; David J Cohen; Philippe Pibarot; Jonathon Leipsic; Rebecca T Hahn; Philipp Blanke; Mathew R Williams; James M McCabe; David L Brown; Vasilis Babaliaros; Scott Goldman; Wilson Y Szeto; Philippe Genereux; Ashish Pershad; Stuart J Pocock; Maria C Alu; John G Webb; Craig R Smith Journal: N Engl J Med Date: 2019-03-16 Impact factor: 91.245
Authors: Raj R Makkar; Gregory Fontana; Hasan Jilaihawi; Tarun Chakravarty; Klaus F Kofoed; Ole De Backer; Federico M Asch; Carlos E Ruiz; Niels T Olsen; Alfredo Trento; John Friedman; Daniel Berman; Wen Cheng; Mohammad Kashif; Vladimir Jelnin; Chad A Kliger; Hongfei Guo; Augusto D Pichard; Neil J Weissman; Samir Kapadia; Eric Manasse; Deepak L Bhatt; Martin B Leon; Lars Søndergaard Journal: N Engl J Med Date: 2015-10-05 Impact factor: 91.245
Authors: Pascal Vranckx; Stephan Windecker; Robert C Welsh; Marco Valgimigli; Roxana Mehran; George Dangas Journal: Eur Heart J Date: 2017-12-01 Impact factor: 29.983
Authors: Tarun Chakravarty; Lars Søndergaard; John Friedman; Ole De Backer; Daniel Berman; Klaus F Kofoed; Hasan Jilaihawi; Takahiro Shiota; Yigal Abramowitz; Troels H Jørgensen; Tanya Rami; Sharjeel Israr; Gregory Fontana; Martina de Knegt; Andreas Fuchs; Patrick Lyden; Alfredo Trento; Deepak L Bhatt; Martin B Leon; Raj R Makkar Journal: Lancet Date: 2017-03-19 Impact factor: 79.321
Authors: Ole De Backer; George D Dangas; Hasan Jilaihawi; Jonathon A Leipsic; Christian J Terkelsen; Raj Makkar; Annapoorna S Kini; Karsten T Veien; Mohamed Abdel-Wahab; Won-Keun Kim; Prakash Balan; Nicolas Van Mieghem; Ole N Mathiassen; Raban V Jeger; Martin Arnold; Roxana Mehran; Ana H C Guimarães; Bjarne L Nørgaard; Klaus F Kofoed; Philipp Blanke; Stephan Windecker; Lars Søndergaard Journal: N Engl J Med Date: 2019-11-16 Impact factor: 91.245
Authors: Martin B Leon; Craig R Smith; Michael J Mack; Raj R Makkar; Lars G Svensson; Susheel K Kodali; Vinod H Thourani; E Murat Tuzcu; D Craig Miller; Howard C Herrmann; Darshan Doshi; David J Cohen; Augusto D Pichard; Samir Kapadia; Todd Dewey; Vasilis Babaliaros; Wilson Y Szeto; Mathew R Williams; Dean Kereiakes; Alan Zajarias; Kevin L Greason; Brian K Whisenant; Robert W Hodson; Jeffrey W Moses; Alfredo Trento; David L Brown; William F Fearon; Philippe Pibarot; Rebecca T Hahn; Wael A Jaber; William N Anderson; Maria C Alu; John G Webb Journal: N Engl J Med Date: 2016-04-02 Impact factor: 91.245